Heart failure patients may benefit from drug optimization clinic after defibrillator implant
NCT ID NCT04505007
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a clinic led by a heart failure nurse could help patients with heart failure get the right medications after getting an implantable defibrillator (ICD) or cardiac resynchronization therapy (CRT). The goal was to see if this approach improved heart function and reduced hospital visits. The study included 29 adults who had an ICD or CRT implanted between 2002 and 2019.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
29 people
The number who actually took part.
- Started
-
Jun 2021
- Finished
-
Aug 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: \- patients who underwent ICD or CRT (pacemaker or defibrillator) implantation therapy at the QEII Health Sciences Centre between 2002 and 2019 and had a left ventricular ejection fraction ≤ 35% at the time of the initial implantation. Exclusion Criteria: * unable to provide informed consent, has a life expectancy of less than one year, dementia, cirrhosis, or metastatic malignancy. * Patients who underwent primary prevention ICD implantation for arrhythmogenic right ventricular cardiomyopathy (ARVC), ion channelopathies, hypertrophic cardiomyopathy, or infiltrative cardiomyopathy will be excluded from this analysis.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heart failure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
QEII Health Sciences Centre
Halifax, Nova Scotia, B3H 3A7, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a handheld ultrasound help clinics spot heart failure sooner?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can daily mindful breathing ease heart failure symptoms?
- Can a smartphone app keep heart failure patients out of the hospital?
- Does your morning coffee stir up heart rhythm trouble?
- Can better training get doctors to talk about what matters most to dying veterans?